Tenon Medical is a Los Gatos sacroiliac fusion specialist that finally has a commercial story worth arguing about, and a capital structure that keeps eating that story. The second quarter showed the dual-platform bet after last summer's SImmetry Plus purchase is lifting procedure volume and unit profit. The investment debate is whether that operating turn can outrun a financing treadmill that has already forced a reverse split, a going-concern paragraph, and a string of warrant-heavy raises.
The commercial print is not a rounding error on a tiny base. Revenue reached about $1.3 million as Catamaran and SImmetry Plus cases stacked. Gross margin printed at 64 percent once volume started covering factory overhead. Those are real operating gains rather than accounting noise. They still sit inside a cash pile that was already thin at mid-year and an equity account that had flipped into deficit before the summer raise. The later note repayment removed a discounted-conversion overhang, but only after fresh shares and warrants paid for the privilege.
July brought the busiest surgical month on record after physician and distributor training events nearly doubled versus the prior half-year. An updated FDA clearance moved several Catamaran instruments from disposable to reusable, which is the first real cost takeout on the implant kit. The question the next two prints have to answer is whether case growth can fund the commercial build without another reverse-split-and-raise cycle.